Regeneron's Eylea overtakes Lucentis with 2014 US sales
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals reported $1.74bn in US sales for Eylea (aflibercept) in 2014, surpassing Roche's $1.7bn US total for the competing biologic Lucentis (ranibizumab), and a slightly higher Eylea growth rate is expected in 2015 based on increased use and new indications.